Multimodal integration of VI-RADS, radiomics, and deep learning features for prediction of pathology and prognosis in bladder cancer. This is an ASCO Meeting Abstract from the 2026 ASCO Genitourinary ...
Initiated Phase 1/2 study expansion for IDE397, IDEAYA's MAT2A inhibitor, in combination with Trodelvy ®, Gilead's Trop-2 directed ADC, in MTAP-deletion urothelial cancer based on preliminary safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results